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I. General Introduction 
    Abuse of psychostimulant such as methamphetamine (METH) is a worldwide 
public health problem. METH is a powerfully addictive stimulant associated with 
serious health conditions, cognitive impairment, aggression, psychotic symptoms and 
behavior, and potential heart and brain damage. It is well known that METH induces 
schizophrenia-like symptoms, which is including positive symptoms and cognitive 
impairment, and neurotoxicity in mesolimbic dopamine system in humans. In addition, 
many psychiatric and psychological symptoms, such as depression, agitation and 
cognitive impairment, emerge after withdrawal from the repeated use of METH in 
humans. Whereas, prior studies revealed that depression is a core symptom of METH 
withdrawal during the first several weeks of abstinence. Although METH abuse elicits 
neurotoxicity at dopaminergic terminals and withdrawal symptoms, the precise 
pathogenesis remains unknown. Development of novel therapeutic agents for METH 
abuse is a most urgent problem.  
   Several evidence suggests that brain-derived neurotrophic factor (BDNF) along 
with its specific receptor, tropomyosin- related kinase (TrkB) signaling plays a role in 
the abnormality behavioral in rodents after the psychostimulants; which also may play 
an important role in the pathophysiology of depression. Previous studies revealed that 
injection of antibodies against BDNF or TrkB into the nucleus accumbens (NAc) 
attenuated the stimulation of dopamine (DA) release and behavioral abnormalities seen 
after METH exposure. Moreover, TrkB antagonist increased amphetamine-induced 
vertical activity. Furthermore, withdrawal from repeated use of stimulants causes 
depression-like behavior neurochemical alterations in the NAc in rodents, included 
repeated treatment with stimulants produces a long-lasting increase in the number of 
branched and density of dendritic spines in the NAc. Taken together, BDNF-TrkB 
signaling in ventral tegmental area (VTA)-NAc may plays a role in the behavioral 
abnormalities and structural plasticity of the VTA-NAc circuit after stimulant 
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administration and subsequence withdrawal. This would make BDNF-TrkB signaling 
may be a potential therapeutic target for neuropsychiatric disorder such as 
psychostimulant-related psychosis, schizophrenia and depression.  
   This study, therefore, consists of three parts: I. To determine whether 
7,8-dihydroxyflavone (7,8-DHF), a novel high-affinity TrkB agonist, could attenuate 
behavioral abnormalities as well as dopaminergic neurotoxicity in striatum of mice 
exposed to METH; II. To determine whether 7,8-DHF could attenuate prepulse 
inhibition (PPI) deficits in mice after the administration of METH; III. To investigate 
whether BDNF-TrkB signaling in the VTA-NAc circuit plays a role in the withdrawal 
symptoms after repeated METH administration. 
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II. CHAPTER Ⅰ 
7,8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral 
abnormalities and neurotoxicity in mice after administration of 
methamphetamine 
 
BACKGROUND 
Methamphetamine (METH) is a powerfully addictive stimulant associated with serious 
health risks such as, cognitive decline, aggression, psychotic symptoms and behavior, 
and potential heart and brain damage. Abuse of METH is now a major worldwide, 
public health problem (National Institute on Drug Abuse, 2002; Barr et al, 2006; 
Hashimoto, 2007; Gonzales et al, 2010; Chen et al, 2010; Colfax et al, 2010; Dean et al, 
2013). It is well known that repeated administration of METH causes neurotoxicity in 
the striatum of rodents and non-human primates by producing long-term depletion of 
dopamine (DA) and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA), as well as DA transporter (DAT), and reduced tyrosine 
hydroxylase (TH) activity (Davidson et al, 2001; Cadet et al, 2003). In addition, levels 
of DA, and concentrations of TH and DAT are reduced in post-mortem striatum samples 
from chronic METH users (Wilson et al, 1996; Davidson et al, 2001). Moreover, 
positron emission tomography studies demonstrate that the density of DAT in the 
caudate/putamen and nucleus accumbens (NAc) of METH users is significantly lower 
than that of healthy controls (Sekine et al, 2001; Volkow et al, 2001). Thus, although 
METH-induced neurotoxicity at dopaminergic terminals is well documented, the precise 
mechanisms promoting this neurotoxicity remain unknown (Cadet et al, 2003; 
Hashimoto, 2007; Chen et al, 2010). 
Accumulating evidence suggests that brain-derived neurotrophic factor (BDNF) along 
with its specific receptor, tropomyosin-related kinase (TrkB) signaling may play a role 
in the behavioral abnormalities seen in rodents after exposure to stimulants.  This 
would make BDNF-TrkB signaling a potential therapeutic target for neuropsychiatric 
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diseases. Injection of antibodies against BDNF or TrkB into the NAc, attenuated the 
stimulation of DA release and behavioral abnormalities seen after METH exposure 
(Narita et al, 2003). Furthermore, K252a, a TrkB antagonist, increased 
amphetamine-induced vertical activity (McGinty et al, 2011). These findings suggest 
that BDNF-TrkB signaling plays a role in the behavioral abnormalities observed after 
stimulant administration.  
7,8-Dihydroxyflavone (7,8-DHF) is a novel, high-affinity TrkB agonist that 
provokes receptor dimerization, auto-phosphorylation, and activation of downstream 
signaling (Jang et al, 2010). Recent studies demonstrate that 7,8-DHF confers a 
neuroprotective, cognitive enhancing and antidepressant effect in animal models (Liu et 
al, 2010; Andero et al, 2011; Blugeot et al, 2011; Devi and Ohno, 2012; Hashimoto, 
2013). The present study was undertaken to determine whether 7,8-DHF could attenuate 
behavioral abnormalities (such as hyperlocomotion and behavioral sensitization as well 
as dopaminergic neurotoxicity in the striatum of mice exposed to METH. 
MATERIALS AND METHODS 
Animals 
Male BALB/cAnCrlCrlj mice (10 weeks old, 23-30 g body weight at the beginning 
of experiments; Charles River Japan Inc., Tokyo, Japan) were housed under a 12-h 
light/12-h dark cycle (lights on from 07:00 to 19:00 hours) at room temperature (22 ± 
2°C; humidity, 55 ± 5%), with free access to food and water. BALB/c mice were used 
since this strain has known sensitivity to METH-induced dopaminergic neurotoxicity 
(Kita et al, 1998; Koike et al, 2005; Zhang et al, 2006; Hagiwara et al, 2009; Chen et al, 
2011). Experimental protocols for this study were approved by the Institutional Animal 
Care and Use Committee of Chiba University. 
Drugs 
METH hydrochloride (d-methamphetamine; Dainippon Pharmaceutical Ltd., Osaka, 
Japan) was dissolved in physiological saline. 7,8-Dihydroxyflavone (7,8-DHF) and 
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5,7-dihydroxyflavone (5,7-DHF: Chrysin) (Tokyo Chemical Industry Co., Ltd., Tokyo, 
Japan) (Figure 1) were dissolved in phosphate-buffered saline containing 17% 
dimethylsulfoxide (DMSO). The compound 5,7-DHF does not bind to TrkB, and is 
currently approved for bodybuilding use in humans. Both 7,8-DHF and 5,7-DHF were 
injected intraperitoneally (i.p.) at a volume of 10 ml/kg body weight. ANA-12 
(N-[2-[[(Hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]-benzo[b]thiophene-
2-carboxamide) (Maybridge, Ltd., Loughborough, Leicestershire, UK) was dissolved in 
physiological saline containing 1% DMSO. METH (3.0 mg/kg expressed as a 
hydrochloride salt) was injected subcutaneously (s.c.) at a volume of 10 ml/kg. Other 
chemicals were purchased from commercial sources.  
Effects of 7,8-DHF on hyperlocomotion after a single administration of METH 
In experiment 1, 30 minutes after a single injection of 7,8-DHF (3.0, 10, or 30 mg/kg, 
i.p.), or vehicle (10 ml/kg, i.p), either METH (3.0 mg/kg, s.c.) or saline (10 ml/kg, s.c.) 
was administered into mice. In experiment 2, 30 minutes after a single injection of 
5,7-DHF (10 mg/kg, i.p.) or vehicle (10 ml/kg, i.p), METH (3.0 mg/kg, s.c.) was 
administered into mice. Locomotor activity was measured over 3 hour period, using an 
animal movement analysis system (SCANET MV-40, Melquest, Toyama, Japan), as 
reported previously (Zhang et al, 2006; Hagiwara et al, 2009; Chen et al, 2011). 
Effects of 7,8-DHF on the development of behavioral sensitization after repeated 
administration of METH 
Thirty two mice were divided into the following four groups: vehicle (10 ml/kg, i.p.) + 
saline (10 ml/kg, s.c.); vehicle (10 ml/kg, i.p.) + METH (3.0 mg/kg, s.c.); 7,8-DHF (10 
Figure 1. Chemical structure of 7,8-DHF and 5,7-DHF 
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mg/kg, i.p.) + METH (3.0 mg/kg, s.c.) and 7,8-DHF (10 mg/kg, i.p.) + vehicle (10 
ml/kg, s.c.). The interval between the pretreatment injection and second injection was 
30 minutes. After the administration of METH or saline, mice were returned to their 
home cages. This cycle of injections was performed on each mouse, for 5 consecutive 
days. Seven days after the final administration, all mice were given a low dose of 
METH (1.0 mg/kg, s.c.), and locomotor activity was measured as described above 
(Zhang et al, 2006; Hagiwara et al, 2009; Chen et al, 2011). 
METH-induced dopaminergic neurotoxicity 
Next, we examined the effects of pretreatment and subsequent treatment with 7,8-DHF 
on METH-induced dopaminergic neurotoxicity in mice. Thirty minutes after an 
injection of vehicle (10 ml/kg, i.p.), 7,8-DHF (10 mg/kg, i.p.), 7,8-DHF (10 mg/kg, i.p.) 
+ ANA-12 (0.5 mg/kg, i.p.), or ANA-12 (0.5 mg/kg, i.p.), mice received three injections 
of METH (3.0 mg/kg, s.c.) or vehicle (10 ml/kg, s.c.), at 3-hour intervals. Next, either 
vehicle (10 ml/kg, i.p.), 7,8-DHF (10 mg/kg, i.p.), 7,8-DHF (10 mg/kg, i.p.) + ANA-12 
(0.5 mg/kg, i.p.), or ANA-12 (0.5 mg/kg, i.p.) was administered to mice, 12 hours after 
the first administration of vehicle or 7,8-DHF, 7,8-DHF + ANA-12, or ANA-12 (day 1). 
Rectal temperatures were measured using a TD-320 thermometer coupled to a rectal 
probe (Shibaura Electronics Co., Ltd., Saitama, Japan), and temperatures were recorded 
30 minutes before pretreatment injections and then at 4, 7, and 24 hours after the first 
injection of METH or vehicle. Mice received two daily injections (12-hour intervals) of 
either vehicle (10 ml/kg, i.p.), 7,8-DHF (10 mg/kg, i.p.), 7,8-DHF (10 mg/kg, i.p.) + 
ANA-12 (0.5 mg/kg, i.p.), or ANA-12 (0.5 mg/kg, i.p.), for 2 consecutive days (days 2 
and 3). The treatment schedule was as previously reported and used to examine both the 
prophylactic and therapeutic effects of 7,8-DHF (Zhang et al, 2006; Hagiwara et al, 
2009; Chen et al, 2011).  
Immunohistochemical detection of DAT, and MAC1 in mouse brains 
Immunohistochemistry was performed on mouse brain sections, as reported previously 
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(Koike et al, 2005; Zhang et al, 2006; Hagiwara et al, 2009; Chen et al, 2011). Three 
days (day 4) after the administration of METH (3.0 mg/kg ×3 at 3-hour intervals), 
mice were deeply anesthetized with sodium pentobarbital and perfused transcardially 
with 10 ml of isotonic saline, followed by 40 ml of ice-cold 4% paraformaldehyde in 
0.1 M phosphate buffer (pH 7.4). Brains were removed from the skulls and postfixed 
overnight at 4°C. For immunohistochemical analysis, 50-µM-thick serial coronal 
sections of brain tissue were cut in ice-cold, 0.01 M phosphate buffered saline (PBS; 
pH7.5), using a vibrating blade microtome (VT1000S, Leica Microsystems AG, Wetzlar, 
Germany). Brain sections (Bregma 0.86 - 1.54 mm) were identified according to 
stereotaxic coordinates in Franklin and Paxinos’ Mouse Brain (Franklin and Paxinos, 
1997). Free-floating sections were treated with 0.3% H2O2 in 0.05 M Tris-HCl saline 
(TBS) for 30 minutes, and blocked in TBS containing 0.2% Triton X-100 (TBST) and 
1.5% normal serum for 1 hour, at room temperature. Samples were then incubated for 
36 hours at 4°C, with rat anti-DAT antibody (1:10,000, Cat. No: MAB 369, Chemicon 
International Inc., Temecula, CA, USA), or rat anti-MAC1 (CD11b) antibody (1:1000, 
Cat. No: MCA74G, Serotec Ltd., Oxford, UK). The sections were washed twice in 
TBST, and processed according to the avidin-biotin-peroxidase method (Vectastain Elite 
ABC, Vector Laboratories, Inc., Burlingame, CA, USA). Sections were then incubated 
for 5 minutes in a solution of 0.15 mg/ml diaminobenzidine, containing 0.01% H2O2. 
The sections were mounted on gelatinized slides, dehydrated, cleared, and coverslipped 
under Permount® (Fisher Scientific, Fair Lawn, NJ, USA). Next, sections were imaged, 
and the staining intensity of DAT immunoreactivity in the anterior regions (0.25 mm2) 
of the striatum was analyzed using a light microscope equipped with a CCD camera 
(Olympus IX70) and the SCION IMAGE software package. MAC1 immunoreactivity 
(activated microglia) was quantified in the anterior regions (0.018 mm2) of the striatum, 
in a blinded manner. Four sections from each mouse were used for the quantitative 
analyses of DAT (n=8-15 per group), and MAC1 (n=8 or 9 per group) 
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immunoreactivity. 
Statistical analysis 
Data were presented as the mean ± standard error of the mean (SEM). Data were 
analyzed by one-way, two-way/three-way or repeated measures analysis of variance 
(ANOVA). When appropriate, post-hoc comparisons were performed using the 
Bonferroni/Dunn test. The p values of less than 0.05 were considered statistically 
significant. 
RESULTS 
7,8-DHF, but not 5,7-DHF, attenuated hyperlocomotion in mice after a single 
administration of METH 
A single dose of METH (3.0 mg/kg) markedly increased locomotor activity in mice. 
Three-way ANOVA analysis revealed significant interactions [METH: F (1, 774) = 
341.7, p < 0.001, 7,8-DHF: F (3, 774) = 10.0931.85, p < 0.001, Time effect: F (17, 774) 
= 9.85, p < 0.001; Interaction (METH x Time): F (17, 774) = 14.48, p < 0.001, 
Intercation (7,8-DHF x Time): F (51, 774) = 1.75, p = 0.001]. Post-hoc analysis showed 
that pretreatment with 7,8-DHF (3.0, 10, or 30 mg/kg, 30 minutes before administration 
of METH) attenuated METH-induced hyperlocomotion in mice, in a dose-dependent 
manner (Figure 2). In contrast, 7,8-DHF (30 mg/kg) alone did not alter locomotion in 
non-METH treated mice compared to control animals (Figure 2). In contrast, 5,7-DHF 
(10 mg/kg), an inactive compound at TrkB, had no effect on hyperlocomotion in mice 
pretreated with METH (Figure 3).  
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Figure 2. Effects of 7,8-DHF on hyperlocomotion in mice after a single administration of METH. 
Thirty minutes after injection of vehicle (10 ml/kg, i.p.) or 7,8-DHF (3.0, 10, or 30 mg/kg, i.p.), METH 
(3.0 mg/kg, s.c.) or vehicle (10 ml/kg, s.c.) was administered to mice. Behavior (locomotion) in the 
mice was evaluated. Each value is the mean ± SEM (n=8 per group). *p<0.05, **p<0.01, ***p<0.001 
as compared with vehicle + METH group (Bonferroni/Dunn method). 
Figure 3. 5,7-DHF did not alter hyperlocomotion in mice after a single administration of METH.  
Thirty minutes after i.p. injection of vehicle (10 ml/kg) or 5,7-DHF (10 mg/kg), METH (3.0 mg/kg, s.c.) 
was administered to the mice. Behavior (locomotion) in the mice was evaluated. Each value is the mean
SEM (n=8 per group). 
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7,8-DHF blocked the development of behavioral sensitization after repeated 
administration of METH.  
Repeated administration of METH (3.0 mg/kg/day, once daily for five consecutive 
days) significantly increased METH (1.0 mg/kg)-induced hyperlocomotion in mice 
previously treated with METH, compared with control animals. These results indicate 
the development of behavioral sensitization, by repeated METH administration (Figure 
4). Two-way ANOVA analysis revealed significant differences [METH: F (1, 28) = 4.70, 
p = 0.039, 7,8-DHF: F (1, 28) = 13.07, p = 0.001, Interaction (METH x 7,8-DHF): F (1, 
28) = 12.29, p = 0.002]. Post hoc analysis showed that repeated administration of 
METH significantly (p < 0.001) increased METH (1 mg/kg) induced hyperlocomotion 
in mice previously treated with METH, compared with the control group. Pretreatment 
with 7,8-DHF (10 mg/kg) significantly attenuated the development of this sensitization 
after repeated METH administration. In contrast, locomotion in the 7,8-DHF (10 
mg/kg) treated vehicle group did not differ from that of the control group (Figure 4). 
Hyperthermia induced by repeated administration of METH 
One-way repeated ANOVA analysis revealed significant differences among the six 
groups [F (20, 148) = 13.07, p < 0.001]. Repeated injections of METH (3.0 mg/kg × 3 
at 3-hour intervals) produced significant hyperthermia in mice (Figure 5). Pretreatment 
with 7,8-DHF (10 mg/kg), 7,8-DHF (10 mg/kg) + ANA-12 (0.5 mg/kg), or ANA-12 
(0.5 mg/kg) alone did not affect hyperthermia in these mice (Figure 5). Furthermore, 
treatment with 7,8-DHF (10 mg/kg) alone did not alter rectal temperatures in control 
mice (Figure 5). 
DAT immunohistochemistry 
Repeated dosing with METH (3.0 mg/kg × 3 at 3hourintervals) markedly decreased the 
density of DAT in mouse striatum (Figure 6). One-way ANOVA analysis showed a  
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Figure 4. Effects of 7,8-DHF on the development of behavioral sensitization in mice after the repeated 
administration of METH. Vehicle (10 ml/kg) + Saline (10 ml/kg) group, Vehicle (10 ml/kg) + METH (3.0 
mg/kg) group, 7,8-DHF (10 mg/kg) + METH (3 mg/kg) group, and 7,8-DHF (10 mg/kg) + Saline (10 mg/kg) 
group were treated daily as noted for five consecutive days. Seven days after the final administration of METH, a 
lower dose of METH (1.0 mg/kg, s.c.) was administered to all mice. Behavior (locomotion) was evaluated. Each 
value is the mean ± SEM (n=8 per group). *p<0.05, ***p<0.001 as compared with the vehicle + METH group 
(Bonferroni/Dunn method). 
Figure 5. Effect of 7,8-DHF on METH induced hyperthermia in mice. 
Mice received three injections of vehicle (10 mg/kg, 3-h intervals, s.c.) or METH (10 mg/kg, 3-h intervals, s.c.). 
Vehicle (10 ml/kg, i.p.) was injected into the mice 30 min prior to the first injection of METH. Rectal temperatures 
were recorded 30 min before the first injection of METH or vehicle, and 1 h, 4 h, 7 h, and 24 h after the first METH 
injection. Each value is mean±SEM (n=8-15 per group). ***p<0.0001 as compared with the vehicle + vehicle group 
(Bonferroni/Dunnmethod). 
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significant difference in DAT immunoreactivity in the striatum among the six groups 
[F (5, 61) = 36.61, p < 0.001]. Pretreatment and subsequent treatment with 7,8-DHF 
(10 mg/kg) significantly protected against the reduction of DAT in the striatum, after 
repeated dosing with METH (Figure 6). Furthermore, ANA-12 (0.5 mg/kg) 
significantly (p < 0.001) blocked the protective effects of 7,8-DHF, although ANA-12 
(0.5 mg/kg) alone did not alter DAT density in the striatum of METH treated mice 
(Figure 6). In contrast, 7,8-DHF (10 mg/kg) alone had no effect on the density of DAT 
in the striatum of control mice (Figure 6). 
MAC1 immunohistochemistry 
Three days after the repeated dose of METH (3.0 mg/kg × 3 at 3hour intervals), MAC1 
immunoreactivity increased markedly in the striatum (Figure 7). Two-way ANOVA 
analysis revealed a significant interaction [METH: F (1, 28) = 158.8, p < 0.001, 
7,8-DHF, F (1, 28) = 46.85, p < 0.001, Interaction (METH x 7,8-DHF): F (1, 28) = 
56.45, p < 0.001]. Post hoc analysis showed that pretreatment and subsequent 
administration of 7,8-DHF (10 mg/kg), significantly (p < 0.001) attenuated the increase 
in MAC1 immunoreactive cell numbers in the striatum. In contrast, treatment with 
7,8-DHF (10 mg/kg) alone had no effect on MAC1 immunoreactivity in the striatum of 
control mice (Figure 7). 
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Figure 6. Effects of 7,8-DHF on the reduction in DAT density in the striatum after the 
repeated administration of METH. (A) Vehicle+saline, (B) vehicle+METH, (C) 
7,8-DHF+METH, (D) 7,8-DHF/ANA-12+METH, (E) ANA-12+METH, and (F) 7,8-DHF+saline. 
Thirty minutes after i.p. injection of 7,8-DHF (10mg/kg), 7,8-DHF (10mg/kg)+ANA-12 
(0.5mg/kg), ANA-12 (0.5mg/kg), or vehicle (10ml/kg), the mice received three injection of METH 
(3mg/kg, s.c.) or saline (10mg/kg, s.c.) at 3h intervals (day1). Then, vehicle (10ml/kg), 7,8-DHF 
(10mg/kg), 7,8-DHF (10mg/kg)+ANA-12 (0.5mg/kg), or ANA-12 (0.5mg/kg) was administered to 
the mice 12h after the first administration of vehicle, 7,8-DHF, or ANA-12 (day1). The mice was 
received two daily (12h intervals) injections of vehicle (10ml/kg), 7,8-DHF (10mg/kg), 7,8-DHF 
(10mg/kg)+ANA-12 (0.5mg/kg), or ANA-12 (0.5mg/kg) for two consecutive days (dyas2 and 3). 
The mice were perfused 3 days after the administration of METH (day4). (A-F) Representative 
photomicrographs showing the DAT immunoreactivity staining was determined for each group and 
was expressed as a percentage of that of matched control mice. Each value is the mean±SEM (n = 
8-15 per group). ***p<0.001 as compared with the vehicle + METH group, ##p<0.01 as compared 
with 7,8-DHF+METH group (Bonferroni/Dunn method). 
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Figure 7, Effects of 7,8-DHF on microglial activation in the mouse striatum after repeated 
administration of METH. (A) Vehicle + saline, (B) vehicle + METH, (C) 7,8-DHF + METH, 
and (D) 7,8-DHF + saline. Thirty minutes after i.p. injection of 7,8-DHF (10mg/kg) or vehicle 
(10ml/kg), the mice received three injections of METH (3mg/kg, s.c.) or saline (10ml/kg, s.c.) at 
3h intervals (day 1). Then, vehicle (10 ml/kg, i.p.) or 7,8-DHF (10 mg/kg, i.p.) was administered 
to the mice 12 h after the first administration of vehicle or 7,8-DHF (day 1). The mice received 
two daily (12-h intervals) injections of 7,8-DHF (10 mg/kg, i.p.) or vehicle (10 ml/kg, i.p.) for 2 
consecutive days (days 2 and 3). The mice were perfused 3 days after the administration of 
METH (day 4). Representative photomicrographs depicting MAC1 immunohistochemistry 
(activated microglia) in the striatum of mice (A-D). The mean value representing the staining of 
activated microglia was determined for each group and was expressed as a percentage of that of 
matched control mice (E). The number of activated microglia in the mouse striatum was counted 
based on one microscopic view (×200)(F). Each value was the mean ± SEM (n=8 or 9 per group). 
***p<0.001 as compared with the vehicle + METH group (Bonferroni/Dunn method). Scale bar 
in A-D was 50 µm. 
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DISCUSSION 
A major finding of this study is that 7,8-DHF, but not 5,7-DHF, attenuated behavioral 
abnormalities such as hyperlocomotion and behavioral sensitization in mice, after the 
administration of METH. We also found that 7,8-DHF conferred protection against 
dopaminergic neurotoxicity in the striatum, after repeated METH exposure. To the best 
of our knowledge, this is the first report showing that TrkB agonism can ameliorate 
behavioral abnormalities and neurotoxicity in rodents after METH exposure. 
Furthermore, ANA-12, a potent TrkB antagonist, blocked the protective effects of 
7,8-DHF on METH-induced dopaminergic neurotoxicity in the striatum This strongly 
implicates TrkB signaling in the mechanistic action of 7,8-DHF. Interestingly, several 
studies suggest that BDNF-TrkB signaling plays a causal role in the plasticity observed 
in other abused drugs, including cocaine and morphine (Berhow et al, 1995; Graham et 
al, 2009; Russo et al, 2009; Lobo et al, 2010). A recent clinical study showed that serum 
levels of BDNF were significantly lower in METH abusers (n = 59) during early 
withdrawal, compared with age- and sex-matched healthy controls (n = 59) (Chen et al, 
2013), suggesting that METH abusers may suffer severe dysfunction of BDNF-TrkB 
signaling. Taken together, these findings highlight TrkB agonists such as 7,8-DHF as 
promising therapeutic drugs for the multiple symptoms associated with METH abuse in 
humans. 
It is well known that METH mediates its acute pharmacological effects through 
elevated extracellular DA levels. This is achieved by both the release of DA from 
presynaptic terminals and the inhibition of DA re-uptake (Seiden et al, 1993). Recently, 
we reported that 7,8-DHF attenuated increases of extracellular DA in the striatum, after 
a single dose of METH (Ren et al, 2013). These findings suggest that the inhibition of 
METH-induced DA release by 7,8-DHF may, at least in part, explain the action of 
7,8-DHF with respect to METH-induced behavioral changes in mice. Nonetheless, 
further detailed studies on the ability of 7,8-DHF to ameliorate METH-associated acute 
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neurochemical and behavioral abnormalities will be necessary. 
Repeated exposure to METH results in a progressively enhanced and enduring 
behavioral response to the drug, a phenomenon known as behavioral sensitization. A 
number of behavioral, neurochemical, biochemical, and molecular studies have shown 
that the initiation of this complex process involves the interaction of several 
neurotransmitters, neuropeptides, neurotrophic factors, and their associated receptor 
signaling pathways (Robinson and Becker, 1986; Pierce and Kalivas, 1997; White and 
Kalivas, 1998; Vanderschuren and Kalivas, 2000). It has been reported that DA release 
and the induction of DA-related behavioral abnormalities by METH were significantly 
suppressed by pretreatment with intra-nucleus accumbens injections of BDNF or TrkB 
antibodies (Narita et al, 2003). Furthermore, an intra-striatal infusion of K252a, a TrkB 
antagonist, increased amphetamine-induced vertical activity, but not the total distance 
traveled, in rats (McGinty et al, 2011). These findings add weight to the theory that 
BDNF-TrkB signaling may play a role in METH (or amphetamine)-induced behavioral 
changes in rodents. Therefore, it is likely that 7,8-DHF induced stimulation of TrkB 
signaling may act to inhibit the development of behavioral sensitization after repeated 
METH administration. Again, further studies are necessary to fully elucidate these 
mechanisms.  
To examine whether 7,8-DHF and ANA-12 affect DAT function in mouse 
striatum, we examined the effects of both compounds on [3H]WIN 35,428 binding to 
DAT in homogenates from mouse striatum and [3H]DA uptake into synaptosome from 
mouse striatum. We found that neither 7,8-DHF nor ANA-12 bound DAT in the mouse 
striatum (Table 1). Furthermore, we also found that neither 7,8-DHF nor ANA-12 
affected DAT function in the mouse striatum (Table 2). Therefore, it is unlikely that the 
inhibition of DAT by 7,8-DHF plays a role in the mechanisms driving METH-induced 
neurotoxicity.  
A number of studies suggest that METH-induced neurotoxicity in DA nerve 
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terminals in the striatum is associated with microglial activation (Guilarte et al, 2003; 
LaVoie et al, 2004; Thomas et al, 2004; Thomas and Kuhn, 2005; Zhang et al, 2006; 
Chen et al, 2011). General trends on the temporal- and dose-response relationships 
between METH-induced neurotoxicity and microglial activation suggest that this 
activation contributes to METH-induced neurotoxicity in the striatum (Thomas et al, 
2004). In this study, we found that 7,8-DHF attenuated the activation of microglia in the 
striatum after repeated dosing with METH. If 7,8-DHF can protect against 
METH-induced neurotoxicity by influencing mechanisms upstream of DA terminals, 
the lack of microglial activation may be more logically seen as a consequence, rather 
than a cause of neurotoxicity. Nonetheless, a further detailed study will be needed to 
examine this issue. 
A number of studies indicate that neurotoxic doses of METH cause hyperthermia, 
and that hypothermia can suppress METH-induced neurotoxicity, suggesting a role for 
body temperature in METH-induced dopaminergic neurotoxicity (Albers and Sonsalla, 
1995; Ali et al, 1996). However, we found no evidence that 7,8-DHF altered 
METH-induced hyperthermia. Therefore, it is unlikely that the protective effects of 
7,8-DHF on METH-induced neurotoxicity are mediated through regulation of body 
temperature in mice. 
In conclusion, our study demonstrated that 7,8-DHF, a TrkB agonist, inhibited 
changes such as acute hyperlocomotion, the development of behavioral sensitization, 
and dopaminergic neurotoxicity, typically induced by repeated exposure to METH. 
These findings make TrkB agonists potential therapeutic agents for the treatment of 
multiple symptoms associated with METH abuse. 
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Table 1.  
Effects of 7,8-DHF and ANA-12 on [3H]WIN 35,428 binding to DAT in mouse 
straitum. 
Compounds 
Concentration (mol/L) 
1×10-6 1×10-5 
Inhibition (%) 
7,8-DHF 3.30 0.00 
ANA-12 2.46 13.71 
GBR12909 D 99.52 
D: Not assayed 
Data are expressed as the mean values of duplicate samples. 
The inhibition ratio was calculated from “100 – binding ratio.” 
Binding ratio: [(B - N) / (B0 - N)] × 100 (%) 
B: Bound radioactivity in the presence of test compound (individual value) 
B0: Total bound radioactivity in the absence of test compound (mean value) 
N: Non-specific bound radioactivity (mean value) 
GBR 12909: A specific and potent DAT inhibitor 
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Table 2.  
Effects of 7,8-DHF and ANA-12 on [3H]DA uptake into synaptosame from mouse 
striatum 
Compounds 
Concentration (10-5 mol/L) 
Inhibition (%) 
7,8-DHF 4.57 
ANA-12 6.54 
Data are expressed as the mean values of duplicate samples. 
The inhibition ratio was calculated from “100 – binding ratio.” 
Binding ratio: [(B - N) / (B0 - N)] × 100 (%) 
B: Bound radioactivity in the presence of test compound at 37°C. 
B0: Total bound radioactivity in the absence of test compound at 37°C. 
N: Non-specific bound radioactivity at 4°C. 
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III. CHAPTER II
Effects of TrkB agonist 7,8-dihydroxyflavone on sensory gating 
deficits in mice after administration of methamphetamine
 
1. Introduction 
Abuse of the psychostimulant methamphetamine (METH) is a worldwide, public health 
problem (Hashimoto, 2007; Gonzalaes et al., 2010; Karila et al., 2010; Chen et al., 
2011). The abuse of METH has significant psychiatric and medical consequences, 
including psychosis, dependence, overdose, and death. However, there are currently no 
pharmacological treatments for METH-induced symptoms (Hashimoto, 2007; 
Gonzalaes et al., 2010; Karila et al., 2010; Chen et al., 2011). The psychostimulants, 
such as METH and amphetamine, are known to induce schizophrenia-like symptoms 
including positive symptom and cognitive impairments in humans (Snyder, 1976; 1976; 
Robinson and Becker, 1986; Javitt and Zukin, 1991; Sato et al., 1992; Krystal et al., 
2005; Moncrieff, 2009; Dean et al., 2013).  
Prepulse inhibition (PPI) of the acoustic startle response is a form of sensorimotor 
gating, defined as an inhibition of the startle response when a low intensity stimulus, the 
prepulse, precedes the startling stimulus. Deficits in PPI have been reported in several 
psychiatric disorders including schizophrenia, suggesting that deficient PPI per se or 
abnormalities in neural circuits regulating PPI may cause some symptoms of 
schizophrenia (Braff and Geyer, 1990; Swedlow et al., 1994; Perry et al., 1999; Geyer et 
al., 2001). Deficits of PPI in patients with schizophrenia can be mimicked in rodents by 
treatment with METH (Dai et al., 2004; Arai et al., 2008; Mizoguchi et al., 2009). 
Therefore, the pharmacological model of METH-induced PPI deficits is one of the 
excellent predictors of antipsychotic activity.  
Both the stimulation of dopamine release and induction of dopamine-related 
behavioral abnormalities by METH were significantly suppressed by pretreatment with 
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intra-nucleus accumbens injection of BDNF antibody or TrkB antibody (Narita et al., 
2003). Furthermore, McGinty et al. (2011) reported that infusion of K252a, a TrkB 
antagonist, increased amphetamine-induced vertical activity, but not total distance 
traveled, suggesting that BDNF-TrkB signaling may play a role in 
amphetamine-induced behavioral abnormalities. Taken together, it is likely that 
BDNF-TrkB signaling plays a role in the behavioral abnormalities in rodents after the 
psychostimulants, and that BDNF-TrkB signaling may be a potential therapeutic target 
for neuropsychiatric disorders such as psychostimulant-related psychosis and 
schizophrenia. Jang et al. (2010) reported the identification of 7,8-dihydroxyflavone 
(7,8-DHF)(Figure 1) as a bioactive high-affinity TrkB agonist that provokes receptor 
dimerization and auto-phosphorylation and activation of downstream signaling. 
Subsequent studies showed that 7,8-DHF had neuroprotective, cognitive enhancing and 
antidepressant effects in animal models (Liu et al., 2010; Andero et al., 2011; Blugeot et 
al., 2011; Devi and Ohno, 2012; Hashimoto, 2013). 
 
The present study was, therefore, undertaken to study whether 7,8-DHF could 
attenuate PPI deficits in mice after the administration of METH. Furthermore, we also 
examined the effects of 5,7-dihydroxyflavone (5,7-DHF)(Figure 1), an inactive ligand, 
on METH-induced PPI deficits. In addition, we examined whether ANA-12, a TrkB 
antagonist (Gazorla eta l., 2011; Hashimoto, 2013)(Figure 1), could block the efficacy 
of 7,8-DHF on METH-induced PPI deficits. Moreover, using in vivo microdialysis 
technique, we examined the effects of 7,8-DHF on METH-induced release of dopamine 
Figure 1. Chemical structures of 7,8-DHF, 5,7-DHF, and ANA-12 
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in the mouse striatum, since dopamine levels in this brain region play an important 
role in METH-induced PPI deficits (Zhang et al., 2007). 
 
2. Materials and methods 
2.1. Animals 
Male ddy mice (8 weeks old) weighing 25–30 g were purchased from SLC Japan 
(Hamamatsu, Shizuoka, Japan). The mice were housed in clear polycarbonate cages 
(22.5×33.8×14.0 cm) in groups of 5 or 6 per cage under a controlled 12/12-h light–dark 
cycle (lights on from 7:00 AM to 7:00 PM), with room temperature at 23 ± 1°C and 
humidity at 55 ± 5%. The mice were given free access to water and food pellets. The 
experimental procedure was approved by the Animal Care and Use Committee of Chiba 
University.  
2.1. Drugs 
7,8-Dihydroxyflavone (7,8-DHF) and 5,7-dihydroxyflavone (5,7-DHF)(Figure 1) were 
purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan), and was dissolved 
in phosphate buffer saline including 17 % dimethyl sulfoxide (DMSO) (Wako Pure 
Chemical Co., Tokyo, Japan). ANA-12, 
N-[2-[[(Hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]-benzo[b]thiophene-2
-carboxamide (Figure 1), was purchased from Maybridge, Ltd. (Loughborough, 
Leicestershire, UK). METH hydrochloride was purchased from Dainippon 
Pharmaceutical Ltd. (Osaka, Japan), and the dose (3.0 mg/kg) of METH was expressed 
as a hydrochloride salt. Other drugs were purchased from commercial sources.  
2.3. Effect of 7,8-DHF and 5,7-DHF on PPI deficits after a single administration of 
METH  
The mice were tested for their acoustic startle reactivity (ASR) in a startle chamber 
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(SR-LAB; San Diego Instruments, San Diego, CA, USA) using the standard methods 
described previously (Zhang et al., 2007; Hashimoto et al., 2008; 2010: Horio et al., 
2009; Tanibuchi et al., 2009; Shirai et al., 2012). The test sessions were begun after an 
initial 10-min acclimation period in the chamber. The mice were subjected to one of six 
trials: (1) pulse alone, as a 40 ms broadband burst; a pulse (40 ms broadband burst) 
preceded by 100 ms with a 20 ms prepulse that was (2) 4 dB, (3) 8 dB, (4) 12 dB, or (5) 
16 dB over background (65 dB); and (6) background only (no stimulus). The amount of 
prepulse inhibition (PPI) was expressed as the percentage decrease in the amplitude of 
the startle reactivity caused by presentation of the prepulse (% PPI). 7,8-DHF (3.0, 10 
or 30 mg/kg), 5,7-DHF (30 mg/kg), 7,8-DHF (30 mg/kg) plus ANA-12 (0.5 mg/kg), 
ANA-12 (0.5 mg/kg) or vehicle (10 ml/kg) was administered intraperitoneally (i.p.) 30 
min (including the 10-min acclimation period) before the machine records, and METH 
(3.0 mg/kg) or saline (10 ml/kg) was administered subcutaneously (s.c.) 10 min 
(including the 10-min acclimation period) before. The PPI test lasted 20 min in total.  
2.4. In vivo microdialysis study 
In vivo microdialysis technique in a conscious mouse was performed by the method 
reported previously (Zhang et al., 2007; Fujita et al., 2012). Mice were anesthetized 
with sodium pentobarbital prior to the stereotaxic implantation of a probe into the 
striatum (+0.1 mm anteroposterior, -2.0 mm mediolateral from the bregma, and -4.0 mm 
dorsoventral with respect to dura), according to the Franklin and Paxinos Atlas (1997). 
Probes were secured onto the skull using stainless-steel screws and dental acrylic. 
Twenty-four hours after surgery, in vivo microdialysis was performed on conscious and 
free-moving mice. Probes were perfused continuously with artificial CSF (147 mM 
NaCl, 4 mM KCl, and 2.3 mM CaCl2) at a rate of 2 µl/min. Vehicle (10 ml/kg, i.p.) or 
7,8-DHF (30 mg/kg, i.p.) was administered into mice before administration of METH 
(3.0 mg/kg, s.c.). The dialysate was collected in 30-min fractions, and dopamine levels 
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in each fraction were measured by high performance liquid chromatography (HPLC), 
with electrochemical detection using a reversed phase column (EICOMPAK PP-ODS 
II, 4.6 x 30 mm, Eicom, Kyoto, Japan) and a mobile phase 2% MeOH/100 mM 
phosphate buffer (pH 5.4) including 50 mg/L disodium EDTA disodium and 500 mg/L 
dodium decane-1-sulfonate. Four samples were obtained in order to establish the 
baseline levels of extracellular dopamine before the administration of METH. 
Statistical Analysis 
The data are presented as the mean ± standard error of the mean (S.E.M.). The PPI data 
were analyzed by multivariate analysis of variance (MANOVA). When appropriate, 
group means at individual dB levels were compared by one-way ANOVA, followed by 
post-hoc LSD test. The results of extracellular dopamine levels were also analyzed by 
repeated one-way ANOVA, followed by the Student’s t-test. Significance for the results 
was set at p < 0.05. 
RESULTS 
Figure 2 shows the effects of 7,8-DHF (3.0, 10 or 30 mg/kg) on METH (3.0 
mg/kg)-induced PPI deficits in mice. The MANOVA analysis of all PPI data revealed 
that there was a significant effect [Wilks lambda = 0.563, p = 0.01]. Subsequent 
ANOVA analysis revealed the significant differences (p < 0.001) at all dB groups (69, 
73, 77, and 81 dB). A post-hoc analysis indicated a significant (p < 0.001) difference in 
PPI deficits between the vehicle + vehicle group and vehicle + METH (3.0 mg/kg) 
group at all dB groups (Figure 2). Pretreatment with 7,8-DHF (3.0, 10 or 30 mg/kg) 
attenuated METH-induced PPI deficits, in a dose dependent manner. Co-administration 
of ANA-12 (0.5 mg/kg) significantly antagonized the effect of 7,8-DHF (30 mg/kg) on 
METH-induced PPI deficits at 81dB. Furthermore, ANA-12 (0.5 mg/kg) did not affect 
METH-induced PPI deficits in mice. In contrast, 5,7-DHF (30 mg/kg) did not affect PPI 
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deficits in mice after administration of METH (3.0 mg/kg) (Figure 2). In addition, 
7,8-DHF (30 mg/kg), or 5,7-DHF (30 mg/kg) did not affect PPI deficits in control 
(saline treated) mice (Figure 2). These findings suggest the role of TrkB signaling in 
the mechanism of action of 7,8-DHF on METH-induced PPI deficits. 
In order to explore the mechanisms by which 7,8-DHF inhibits the 
METH-induced PPI deficits, we used an in vivo microdialysis technique to examine the 
in vivo effects of 7,8-DHF on the METH-induced increase in extracellular dopamine 
levels in the striatum of conscious mice. A single administration of METH (3.0 mg/kg, 
s.c.) caused a marked increase in extracellular dopamine levels in the striatum. Peak 
levels of extracellular dopamine were increased to approximately 7-fold the baseline 
level. The repeated ANOVA analysis revealed significant differences among the two 
groups studied [F (1, 18) = 116.37, p < 0.001]. Subsequent Student’s t-test revealed that 
pretreatment with 7,8-DHF (30 mg/kg, i.p., 30 min prior to METH treatment) 
significantly attenuated METH-induced increases in extracellular dopamine levels in the 
striatum (Figure 3). 
  
33 
 
 
 
 
 
  
Figure 2. The effects of 7,8-DHF, 5-7, DHF, and ANA-12 on PPI deficits in mice after administration of 
METH  
Thirty minutes after i.p. injection of vehicle (10 ml/kg), 7,8-DHF (3.0, 10 or 30 mg/kg), 5,7-DHF (30 mg/kg), 
7,8-DHF (30 mg/kg) plus ANA-12 (0.5 mg/kg), or ANA-12 (0.5 mg/kg), vehicle (saline; 10 ml/kg) or METH (3 
mg/kg) was administered s.c. to the mice. Each value is the mean ± S.E.M. (n=10-14 per group). *p < 0.05, **p < 
0.01, ***p < 0.001 as compared with vehicle + METH group (LSD test). ##p < 0.01 as compared with 7,8-DHF 
(30 mg/kg) + METH group (LSD test).  
 
Figure 3. Effects of 7,8-DHF on extracellular dopamine levels in the striatum after the administration of 
METH. Thirty minutes after i.p. injection of 7,8-DHF (30 mg/kg) or vehicle (10 ml/kg), METH (3.0 mg/kg, s.c.) 
was administered to mice. Extracellular levels of dopamine in the mouse striatum were measured by in vivo 
microdialysis in conscious mice. The basal extracellular levels of dopamine were 5.01 ± 0.96 pg/10 µl in the 
striatum (mean ± S.E.M. of 19 mice). Each value is the mean ± S.E.M. (n=9 or 10 per group). **p < 0.01 
(Student’s t-test) 
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DISCUSSION  
In this study, we found that 7,8-DHF, but not 5,7-DHF, could attenuate PPI deficits in 
mice after administration of METH, and that the efficacy of 7,8-DHF was significantly 
blocked by ANA-12, a TrkB antagonist. In addition, we found that 7,8-DHF 
significantly attenuated the increase of extracellular levels of dopamine in the striatum 
after administration of METH. These findings suggest that TrkB signaling pathway 
plays an important role in the mechanisms of action of the 7,8-DHF on METH-induced 
PPI deficits. Very recently, we reported that 7,8-DHF attenuated the development of 
behavioral sensitization and the neurotoxicity in the striatum after the repeated 
administration of METH (Qian et al. submitted). Given the role of BDNF-TrkB 
signaling pathway in the METH-induced behavioral abnormalities (Narita et al., 2003; 
McGinty et al., 2011), it is possible that TrkB agonists, such as 7,8-DHF, would be a 
potential therapeutic drug for METH-use disorders.  
It is well known that stimulation of the dopamine system can disrupt PPI of the 
acoustic startle response. It is reported that amphetamine (10 mg/kg) failed to disrupt 
PPI in dopamine D2 receptor knock-out mice whereas amphetamine (10 mg/kg) 
significantly disrupted PPI in dopamine D1 receptor knock-out mice (Ralph-Williams et 
al., 2002), suggesting the role of dopamine D2 receptor on amphetamine-induced PPI 
deficits in mice. In addition, it is shown that marked release of dopamine might play a 
role in the PPI deficits after administration of psychostimulants, such as amphetamine 
and METH. Therefore, it is likely that the inhibition of METH-induced dopamine 
release by 7,8-DHF may be implicated in the mechanism of action of 7,8-DHF with 
respect to METH-induced PPI deficits in mice although the mechanism(s) underlying 
the modulation of METH-induced dopamine release by TrkB agonists are currently 
unclear. 
Accumulating reports show that 7,8-DHF has neurotrophic, neuroprotective and 
antidepressant effects in the several animal models (Liu et al., 2010; 2012; Andero et al., 
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2011; Blugeot et al., 2011; Devi and Ohno, 2012; Zeng et al., 2012a; 2012b). 
Interestingly, 7,8-DHF has potent antioxidant and anti-inflammatory properties (Chen 
et al., 2011; Park et al., 2012). It is also reported that microglial activation was 
detected in the brains of METH-treated mice (Zhang et al., 2006; Chen et al., 2012) and 
METH abusers (Sekine et al., 2008), suggesting that chronic self-administration of 
METH can cause neuroinflammation in the brains of METH abusers. A recent clinical 
study showed that serum levels of BDNF were significantly lower in the METH abusers 
(n = 59) during early withdrawal than those of the age- and sex-matched healthy 
controls (n = 59) (Chen et al., 2012), suggesting that METH abusers might have severe 
BDNF dysfunction. Therefore, it is likely that TrkB agonists such as 7,8-DHF would be 
potential therapeutic drug for METH use disorder 
In conclusion, the present study suggests that 7,8-DHF could attenuated 
METH-induced PPI deficits in mice by stimulation of TrkB signaling. Therefore, it is 
likely that TrkB agonists would potentially be used for the treatment of neuropsychiatric 
disorders such as METH-use disorder and schizophrenia. 
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IV. CHAPTER III
BDNF-TrkB signaling in the nucleus accumbens shell plays key role in 
methamphetamine withdrawal symptoms 
 
BACKGROUND 
Abuse of methamphetamine (METH) is currently a major public health problem in the 
world. METH is a powerfully addictive stimulant associated with serious health risks 
such as cognitive impairment, aggression, psychotic symptoms and behavior, and 
potential heart and brain damage (Barr et al, 2006; Hashimoto, 2007; Gonzales et al, 
2010; Chen et al, 2010; Colfax et al, 2010; Sun et al, 2014). In humans, many 
psychiatric and psychological symptoms emerge after withdrawal from the repeated use 
of METH. Major METH withdrawal symptoms include depression (e.g., anhedonia, 
dysphoria, and anergia), agitation and irritability, fatigue (e.g., increased sleeping and 
inactivity), and cognitive impairment. These symptoms may last from a few days to a 
few months (Pannay and Lee, 2011). Withdrawal symptoms have been linked to a 
propensity for METH abuse relapse. METH-dependent subjects exhibit a wide range in 
the severity of depressive symptoms with psychotic symptoms (Zorick et al, 2010). 
Furthermore, depressed METH users benefit less from long-term psychotherapy 
compared with non-depressed METH users (Kay-Lambkin et al, 2011). Thus, 
depression is a core symptom of METH withdrawal during the first several weeks of 
abstinence (Pannay and Lee, 2011; Zorick et al, 2010; Kay-Lambkin et al, 2011; 
McGregor et al, 2005; Zhang et al, 2014). Although antidepressants are used for 
treating these symptoms, their efficacy is limited. To date, the precise mechanisms 
underlying METH withdrawal symptoms remain unknown.  
Accumulating evidence suggests that signaling through the brain-derived 
neurotrophic factor (BDNF) and its specific receptor, tropomyosin-related kinase (TrkB), 
plays an important role in the pathophysiology of depression (Nestler et al, 2002; 
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Hashimoto et al, 2004; Hashimoto, 2010; 2013; Duman and Monteggia, 2006; Nestler 
and Carlezon, 2006; Martinowich et al, 2007; Castrén, 2014). This would make 
BDNF-TrkB signaling a potential therapeutic target for depression. Previously, we 
reported that pretreatment with 7,8-dihydroxyflavone (7,8-DHF), a TrkB agonist, is able 
to attenuate behavioral abnormalities (e.g., hyperlocomotion, prepulse inhibition deficits, 
development of behavioral sensitization) after METH administration (Ren et al, 2013; 
2014). Furthermore, infusion of antibodies against BDNF or TrkB into the nucleus 
accumbens (NAc) attenuates the stimulation of dopamine release and behavioral 
abnormalities after METH exposure (Narita et al, 2003). These findings suggest that 
BDNF-TrkB signaling plays a role in the behavioral abnormalities observed after 
METH administration.  
Withdrawal from repeated use of stimulants, including METH and amphetamine, 
causes neurochemical alterations in the NAc, resulting in a depression-like behavior in 
rodents. Repeated treatment with amphetamine (or METH) increases the number of 
dendritic branches and the density of dendritic spines in the NAc. Furthermore, 
exposure to amphetamine produces a long-lasting increase in the length of dendrites, 
density of dendritic spines, and number of branched spines in the NAc (Robinson and 
Kolb, 1997; 1999; Zhu et al, 2012). Thus, the ability of stimulants to alter the patterns 
of synaptic connectivity in the NAc may contribute to some of the long-term behavioral 
consequences after withdrawal from the repeated amphetamine (or METH) use 
(Robinson and Kolb, 2004; Russo et al, 2009). Accumulating evidence suggests a key 
role of BDNF-TrkB signaling in the structural plasticity of the ventral tegmental area 
(VTA)-NAc circuit in an addiction model (Russo et al, 2009). However, the exact 
molecular mechanisms by which BDNF-TrkB signaling mediates structural plasticity of 
the VTA-NAc circuit remain unknown. Currently, no therapeutic drugs are available for 
withdrawal symptoms (e.g., depression) in METH-dependent subjects. 
The present study was performed to determine whether BDNF-TrkB signaling in 
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the VTA-NAc circuit plays a role in the pathophysiology of METH withdrawal 
symptoms. First, we examined whether withdrawal from repeated METH 
administration caused a depression-like behavior in mice. Second, we examined 
whether BDNF levels were altered in the brain after withdrawal from repeated METH 
administration. Third, we examined the effects of the TrkB antagonist ANA-12 (Cazorla 
et al, 2011; Ren et al, 2013; 2014; Zhang et al, 2015) and the TrkB agonist 7,8-DHF 
(Jang et al, 2010; Ren et al, 2013; 2014; Zhang et al, 2015) on behavioral abnormalities 
(e.g., depression, and behavioral sensitization) and dendritic changes in the VTA-NAc 
circuit after METH withdrawal. 
EXPERIMENTAL PROCEDURES 
Animals 
Male adult C57BL/6 mice (8 weeks old, body weight 20-25g at the beginning of 
experiments; Japan SLC, Inc., Hamamatsu, Japan) were housed under controlled 
temperature and 12 hour light/dark cycles (lights on between 07:00-19:00), with ad 
libitum food and water. All experiments were carried out in accordance with the 
Guideline for Animal Experimentation of Chiba University. This study was approved by 
the Chiba University Institutional Animal Care and Use Committee. 
Drugs 
METH hydrochloride (Dainippon Pharmaceutical Ltd., Osaka, Japan) was dissolved in 
physiological saline, and METH (1.0 or 3.0 mg/kg expressed as a hydrochloride salt) 
was injected subcutaneously (s.c.) at a volume of 10 ml/kg. 7,8-Dihydroxyflavone 
(7,8-DHF) (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) and ANA-12 
(N-[2-[[(Hexahydro-2-oxo-1H-azepin-3-yl)amino]carbonyl]phenyl]-benzo[b]thiophene-
2-carboxamide) (Maybridge, Ltd., Loughborough, Leicestershire, UK) were dissolved 
in phosphate-buffered saline containing 17% dimethylsulfoxide (DMSO). 7,8-DHF or 
ANA-12 were injected intraperitoneally (i.p.) at a volume of 10 ml/kg body weight. 
Ketamine hydrochloride (10 mg/kg; Daiichi-Sankyo Pharmaceutical Ltd., Tokyo, Japan) 
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and paroxetine (Sigma- Aldrich Co., St Louis, MO) were dissolved in the 
physiological saline. Other chemicals were purchased from commercial sources.  
Behavioral tests 
All behavioral tests were performed as following as:  
Locomotion: the mice were placed in experimental cages (length × width × height: 560 
× 560 × 330 mm). Locomotor activity of mice was counted by the SCANET MV-40 
(MELQUEST Co., Ltd., Toyama, Japan), and cumulative exercise was recorded for 60 
minutes. Cages were cleaned between testing session. 
Tail suspension test (TST): The mice were taken from their home cage and a small 
piece of adhesive tape was placed approximately 2 cm from the tip of their tail. A single 
hole was punched in the tape and mice were hung individually, on a hook. The 
immobility time of each mouse was recorded for 10 minutes. Mice were considered 
immobile only when they hung passively and completely motionless.  
Forced swimming test (FST): The mice were placed individually in a cylinder (diameter: 
23 cm; height: 31 cm) containing 15 cm of water, maintained at 23 ± 1℃. Animals were 
tested in an automated forced-swim apparatus using SCANET MV-40 (MELQUEST 
Co., Ltd., Toyama, Japan). Immobility time was calculated from activity time as (total) – 
(active) time, using the apparatus analysis software. Cumulative immobility time was 
scored for 6 minutes during the test. 
Sucrose preference test (SPT): Mice were habituated to a 1% sucrose solution for 24 
hours before the test day. Mice were deprived of water and food for 4 hours from 13:00 
pm to 17:00 pm, followed by a preference test spanning 1 hour with water and 1% 
sucrose, delivered from identical bottles. The bottles containing water and sucrose were 
weighed at the before and end of this period and the sucrose preference (%) was 
determined. 
Behavioral sensitization: All mice were given a low dose of METH (1.0 mg/kg, s.c.), 
and locomotor activity was measured for 90 minutes, as reported previously (Fujita et al, 
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2012; Horio et al, 2012). 
Western blot analysis 
Western blot analysis was performed as previously reported (Zhang et al, 2015; Yang 
et al, 2015). For the western blotting, mice were killed, and prefrontal cortex (PFC), 
CA3 and dentate gyrus (DG) of hippocampus, and NAc were microdissected on ice, and 
stored at -80ºC. Tissue samples were homogenized in Laemmli lysis buffer. Equal 
amount of proteins (10-20 µg) for each sample were measured by DC protein assay kit 
(Bio-Rad, Hercules, CA), and incubated for 5 min at 95ºC with protein buffer (125 mM 
Tris/HCl (pH 6.8), 20% glycerol, 0.1% bromophenol blue, 10% β-mercaptoethanol, 4% 
sodium dodecyl sulfate). The protein samples were loaded into AnykD mini-gels 
(Mini-PROTEAN® TGXTM Precast Gel; Bio-Rad) for electrophoresis. Polyvinylidene 
difluoride (PVDF) membranes with transferred proteins were blocked with 2% BSA 
plus 5% nonfat dry milk in TBST (TBS + 0.1% Tween-20)(for BDNF and proBDNF) or 
2% BSA in PBST (PBS + 0.1% Tween-20)(for GluA1) for 1 h and kept with primary 
antibodies overnight at 4 ºC. The following primary antibody was used: proBDNF 
(1:400, Alomone Labs Ltd, Jerusalem, Israel), BDNF (1:200, H-117, Santa Cruz 
Biotechnology, Inc., CA), phosphorylated-TrkB (Tyr 706) (1:200, Santa Cruz 
Biotechnology, Inc., CA) and TrkB (80E3) (1:1000, Cell Signaling Technology, MA, 
USA), GluA1 (1 µg/mL, Abcam, Cambridge, UK) and β-actin (1:10000, Sigma-Aldrich 
Co., Ltd., St Louis, MO). The next day, blots were washed three times in TBST (or 
PBST) and incubated with horseradish peroxidase conjugated anti-rabbit antibody or 
anti-mouse antibody for 1 h. After final three washes with TBST (or PBST), bands were 
detected using enhanced chemiluminescence (ECL) plus the Western Blotting Detection 
system (GE healthcare Bioscience) and the images were captured with Fuji 
LAS3000-mini imaging system (Fujifilm, Tokyo, Japan), and immunoreactive bands 
were quantified. 
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Golgi staining 
Golgi staining was performed using the FD Rapid GolgiStainTM Kit (FD Neuro 
Technologies, Inc., Columbia, MD), following the manufacturer's instructions, as 
previously reported (Zhang et al, 2015; Yang et al, 2015). Mice were deeply 
anesthetized using CO2 vapor from dry ice, and brains were removed from the skull and 
rinsed in double distilled water. Brains were immersed in the impregnation solution, 
made by mixing equal volumes of Solution A and B, overnight and then stored in fresh 
solution, for 2 weeks in the dark. Brains were transferred into Solution C overnight and 
then stored in fresh solution at 4°C for 1 week, in the dark. Coronal brain sections (100 
µm thickness) were cut on a cryostat (3050S, Leica Microsystems AG, Wetzlar, 
Germany), with the chamber temperature set at -20°C. Each section was mounted in 
Solution C, on saline-coated microscope slides. After absorption of excess solution, 
sections were dried naturally, at room temperature. Dried sections were processed 
following the manufacturer's instructions. Briefly, images of dendrites within PFC, CA3, 
and DG of the hippocampus, NAc, and VTA were captured using a 100× objective with 
a Keyence BZ-9000 GenerationⅡmicroscope (Osaka, Japan). Spines were counted 
along PFC, CA3, DG, NAc, and VTA dendrites starting from their point of origin from 
the primary dendrite. For spine density measurements, all clearly evaluable areas 
containing 50-100 µm of secondary dendrites from each imaged neuron were used. To 
determine relative spine density, spines on multiple dendritic branches from a single 
neuron were counted to obtain an average spine number per 10 µm. For spine number 
measurements, only spines that emerged perpendicular to the dendritic shaft were 
counted. Three neurons per section, six sections per animal and animals (n = 5 or 6) 
were analyzed. The average value for each region, in each individual was obtained. 
These individual averages were then combined to yield a grand average for each region. 
Surgery and bilateral infusion of ANA-12 into NAc shell and NAc core 
Surgery and bilateral injection of ANA-12 into NAc shell was performed as reported 
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previously (Zhang et al, 2015). Mice were anesthetized with pentobarbital (50 mg/kg), 
and placed in a stereotaxic frame. Microinjection probes were placed bilaterally into 
the NAc shell (C1.7 mm anterior/posterior (AP), ± 0.75 mm medial/lateral (ML) 
from the bregma, and − 3.6 mm dorsal/ventral (DV) with respect to the dura), and NAc 
core (C1.54 mm AP, ± 0.75 mm ML from the bregma, and − 3.0 mm DV with respect 
to the dura), according to mouse brain atlas (Paxinos and Watson, 2001). Probes were 
secured onto the skull using stainless-steel screws and dental acrylic. Surgery was 
performed 2 days after final administration of METH (3 mg/kg/day for 5 days). 
ANA-12 (0.1 nmol/L, 0.1 µL/min for 5 min) or vehicle was injected bilaterally in 23 
hours after surgery. Behavioral evaluation was performed 1 hour (locomotion), 3 hours 
(TST) and 5 hours (FST) after a single infusion of ANA-12. 
In vivo microdialysis study 
For in vivo microdialysis study, mice were anesthetized with sodium pentobarbital (50 
mg/kg) prior to the stereotaxic implantation of a probe into the NAc shell (C1.7 mm AP, 
± 0.75 mm ML from the bregma, and − 3.6 mm DV with respect to the dura), according 
to mouse brain atlas (Paxinos and Watson, 2001). Probes were secured onto the skull 
using stainless-steel screws and dental acrylic. Twenty-four hours after surgery, in vivo 
microdialysis was performed at conscious and free-moving mice. Probes were perfused 
continuously with artificial CSF (147 mM NaCl, 4 mM KCl, 2.3 mM CaCl2) at a rate of 
2 µL/min. The dialysate was collected in 30-min fractions, and METH (1 mg/kg, s.c.) 
was administered into all mice. Dopamine levels in each fraction were measured by 
high performance liquid chromatography (HPLC) with electrochemical detection, using 
a reversed phase column (EICOMPAK PP-ODS II, 4.6х30 mm, Eicom, Kyoto, Japan) 
and a mobile phase 2% MeOH/100 mM phosphate buffer (pH 5.4) containing 50 mg/L 
disodium EDTA and 500 mg/L sodium decane-1-sulfonate (Fujita et al, 2012; Horio et 
al, 2012; Ren et al, 2013). Four samples were analyzed to establish baseline levels of 
extracellular dopamine, before the administration of METH. 
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Statistical analysis 
Data were presented as the mean ± standard error of the mean (S.E.M.). The data were 
analyzed by Student t-test or one-way analysis of variance (ANOVA) or two-way 
ANOVA, followed post hoc the Fisher LSD test. The data of in vivo microdialysis were 
analyzed by repeated ANOVA, followed post hoc the Fisher LSD test. The P values of 
less than 0.05 were considered statistically significant. 
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RESULTS  
Depression-like behaviors induced by METH withdrawal  
First, we examined whether the repeated administration of METH (3 mg/kg/day for 5 
days) caused a depression-like behavior in mice. In the TST and FST, the immobility 
time of the METH-treated mice was significantly higher than that of control mice at 
days 8, 12, and 19 (Figure 1A and 1B). In the SPT, sucrose preference (%) in the 
METH-treated group was significantly lower than that of the control group at days 7, 11, 
and 18 (Figure 1A and 1B). In contrast, spontaneous locomotion was similar in both 
groups (Figure 1A and 1B). This data showed that repeated administration of METH 
caused a long-lasting (>14 days after the last METH dosing) depression-like behavior in 
mice. 
Brain levels of BDNF and its precursor proBDNF after repeated METH 
administration 
Because BDNF plays a key role in the depression-like behavior, we measured the levels 
of BDNF (mature form) and its precursor proBDNF protein in the brains of mice treated 
with METH (3 mg/kg/day for 5 days). The levels of proBDNF in the METH-treated 
mice were not different from those of the control mice (Figure 1C and 1D). In contrast, 
in the METH-treated group, the levels of BDNF in the NAc were significantly (t = 
3.925, P < 0.01) higher than those of the control group (Figure 1D). The levels of 
BDNF were similar in both groups in other brain regions, including the dentate gyrus 
(DG) and the CA3 field of the hippocampus, and the prefrontal cortex (PFC) (Figure 
1C and 1D). 
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Figure 1. Depression-like behavior and levels of proBDNF and BDNF in the brain regions after withdrawal 
from repeated METH exposure. A: Schedule of treatment and behavioral tests. Saline (10 ml/kg/day for 5 days) 
or METH (3 mg/kg/day for 5 days) were injected into mice. Behavioral tests were performed at days 7, 11, and 18 
(SPT), and days 8, 12, and 19 (LMT, TST, FST). B: SPT: Sucrose preference of METH-treated mice was 
significantly lower than that of control (saline-treated) mice. LMT: There were no difference between control and 
METH-treated mice. TST and FST: The immobility time of METH-treated mice were significantly higher than that 
of control mice. Each value is the mean ± SEM (n = 7-10 per group). C: Schedule of treatment and Western blot 
analysis. D: Levels of proBDNF and BDNF (mature form) in the PFC, DG, and CA3 of hippocampus were no 
difference between the two groups. Levels of BDNF in the NAc of METH-treated mice were significantly higher 
than those of control mice. Each value is the mean ± S.E.M. (n = 5-8 per group). *P < 0.05, **P < 0.01, ***P < 
0.001 as compared with control (saline-treated) group. SPT: sucrose preference test, LMT: locomotion, TST: tail 
suspension test, FST: forced swimming test. 
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Effects of ANA-12 or 7,8-DHF on depressive-like behavior and TrkB 
phosphorylation after METH withdrawal 
    First, we examined whether a single administration of the TrkB antagonist 
ANA-12 and the TrkB agonist 7,8-DHF could affect behavioral abnormalities 
(depression and behavioral sensitization) in mice after repeated METH administration. 
A single administration of ANA-12 (0.5 mg/kg) or 7,8-DHF (10 mg/kg) did not alter the 
depression-like behavior (Figure 2A and 2B) or the behavioral sensitization (Figure 2C 
and 2D) in mice after repeated administration of METH (3 mg/kg/day for 5 days).  
Next, we examined whether the subchronic administration of ANA-12 or 7,8-DHF 
in mice could correct depression induced by repeated METH administration. After 
repeated METH (3 mg/kg/day for 5 days) administration followed by 1 week 
withdrawal, the mice were administered vehicle (10 ml/kg/day for 14 days), ANA-12 
(0.5 mg/kg/day for 14 days), or 7,8-DHF (10 mg/kg/day for 14 days). Behavioral tests 
for depression-like behavior were performed 3 and 5 days after the end of the treatment 
(Figure 3A). One-way ANOVA revealed statistical differences among the five groups 
[LMT: F (4, 41) = 1.072, P = 0.383; TST: F (4, 38) = 5.823, P = 0.001; FST: F (4, 31) = 3.796, 
P = 0.013; SPT: F (4, 37) = 7.581, P < 0.001]. Subchronic administration of ANA-12, but 
not 7,8-DHF, significantly improved the increased immobility time of TST and FST, 
and the decreased sucrose preference of SPT in mice after repeated METH 
administration (Figure 3B).  
The same experiment was performed a second time, brain samples were obtained 
at day 28. Subsequently, we performed Western blot analysis of BDNF and proBDNF in 
NAc (Figure 3C). Treatment with ANA-12 or 7,8-DHF did not alter increased levels of 
BDNF in the NAc of METH-tread mice (Figure 3D). In contrast, treatment with 
ANA-12, but not 7,8-DHF, significantly attenuated an increase of p-TrkB in the NAc of 
METH treated mice (Figure 3D). One-way ANOVA revealed statistical differences 
among the four groups [p-TrkB: F (3, 18) = 9.315, P < 0.001]. There were no differences 
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for proBDNF and TrkB among the four group. 
Figure 2. Lack of effects of ANA-12 and 7,8-DHF on depression-like behavior and behavioral sensitization 
in mice after withdrawal from repeated METH exposure. 
A: Schedule of treatment and behavioral tests. Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 days) were 
injected into mice from day 1 to day 5. After 1-week withdrawal, vehicle (10 ml/kg), ANA-12 (ANA: 0.5 mg/kg), or 7,8-DHF 
(DHF: 10 mg/kg) were administered i.p. (day 8). LMT, TST, FST were performed at 1, 3, and 5 hours after injection. SPT was 
performed at day 10. B: LMT: There were no differences among the four groups. TST and FST: Increased immobility time of 
METH-treated mice were not altered by subsequent single administration of ANA-12 or 7,8-DHF. SPT: Decreased sucrose 
preference of METH-treated mice was not altered by subsequent single administration of ANA-12 or 7,8-DHF. Each value is 
the mean ± S.E.M. (n = 6-8 per group). *P < 0.05, **P < 0.01, ***P < 0.001 as compared with METH + vehicle group. SPT: 
sucrose preference test, LMT: locomotion, TST: tail suspension test, FST: forced swimming test. C: Schedule of treatment and 
behavioral test. Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 days) were injected into mice from day 1 to day 
5. After 1-week withdrawal, vehicle (10 ml/kg), ANA-12 (ANA: 0.5 mg/kg), or 7,8-DHF (DHF: 10 mg/kg) were administered 
i.p. (day 8). METH (1 mg/kg) was injected s.c. into all mice 0.5 hour after injection. D: The established behavioral sensitization 
after the repeated METH (3 mg/kg/day for 5 days) exposure was not altered by subsequent single administration of ANA-12 or 
7,8-DHF. Each value is the mean ± S.E.M. (n = 7 or 8 per group). ***P < 0.001 as compared with METH + vehicle group. N.S.: 
no significance. 
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Figure 3. Effects of ANA-12 and 7,8-DHF on depression-like behavior and behavioral 
sensitization in mice after withdrawal from repeated METH exposure. A: Schedule of treatment 
and behavioral tests. Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 days) were 
injected into mice from day 1 to day 5. After 1-week withdrawal, vehicle (10 ml/kg/day), ANA-12 
(ANA: 0.5 mg/kg/day), or 7,8-DHF (DHF: 10 mg/kg/day) were administered for 14 days (days 
12-25). Behavioral tests were performed at days 28 (LMT, TST, FST) and 30 (SPT). B: LMT: There 
were no differences among the five groups. TST and FST: Increased immobility time of 
METH-treated mice were significantly attenuated by subsequently repeated administration of 
ANA-12, but not 7,8-DHF. SPT: Decreased sucrose preference of METH-treated mice was 
significantly attenuated by subsequently repeated administration of ANA-12, but not 7,8-DHF. Each 
value is the mean ± S.E.M. (n = 6-8 per group). *P < 0.05, **P < 0.01, ***P < 0.001 as compared with 
METH + vehicle group. SPT: sucrose preference test, LMT: locomotion, TST: tail suspension test, 
FST: forced swimming test. 
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Figure 3. Effects of ANA-12 and 7,8-DHF on depression-like behavior and behavioral 
sensitization in mice after withdrawal from repeated METH exposure. C: Schedule of treatment 
and tissue collection. Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 days) were 
injected into mice from day 1 to day 5. After 1-week withdrawal, vehicle (10 ml/kg/day), ANA-12 
(ANA: 0.5 mg/kg/day), or 7,8-DHF (DHF: 10 mg/kg/day) were administered for 14 days (days 
12-25). Brain samples were collected at day 28. D: Increased levels of BDNF in the NAc was not 
altered by subsequent repeated administration of ANA-12, or 7,8-DHF. Increased levels of p-TrkB 
was significantly attenuated by subsequent repeated administration of ANA-12, but not 7,8-DHF. 
Each value is the mean ± S.E.M. (n = 5 or 6 per group). ***P < 0.001 as compared with METH + 
vehicle group. N.S.: not significant.  
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Effects of ANA-12 or 7,8-DHF on behavioral sensitization after METH withdrawal 
    Next, we examined whether the subchronic administration of ANA-12 or 
7,8-DHF in mice could correct the behavioral sensitization induced by repeated 
METH administration. After repeated METH (3 mg/kg/day for 5 days) administration 
followed by 1 week withdrawal, the mice were administered vehicle (10 ml/kg/day for 
14 days), ANA-12 (0.5 mg/kg/day for 14 days), or 7,8-DHF (10 mg/kg/day for 14 days). 
Behavioral test was performed 3 days after the end of the treatment, the mice were 
injected METH (1 mg/kg, s.c.) on the third day (Figure 4A). One-way ANOVA 
revealed a significant difference among the four groups [F (3, 27) = 19.49, P < 0.001]. 
Behavioral sensitization induced by the repeated administration of METH was 
significantly (P < 0.001) improved by subsequent subchronic administration of ANA-12, 
but not 7,8-DHF (Figure 4B). 
The same experiment was performed a second time. After the repeated METH (3 
mg/kg/day for 5 days) administration and 1-week withdrawal, mice were administered 
vehicle (10 ml/kg/day for 14 days) or ANA-12 (0.5 mg/kg/day for 14 days). Surgery 
was performed 2 days after the final administration, followed by in vivo microdialysis at 
free-moving mice 1 day after the surgery. Then METH (1 mg/kg, s.c.) was administered 
to all mice (Figure 4C). Repeated ANOVA analysis revealed a significant difference 
among the three groups [F (2, 13) = 13.76, P < 0.001]. An increase of extracellular 
dopamine in the NAc shell of METH-treated mice after a single administration of 
METH (1 mg/kg) was significantly attenuated by subsequent repeated administration of 
ANA-12 (Figure 4D). 
These findings suggest that behavioral abnormalities (depression and behavioral 
sensitization) in mice after METH withdrawal were improved by subsequent repeated 
administration of the TrkB antagonist ANA-12, but not TrkB agonist 7,8-DHF. 
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Figure 4. Effects of ANA-12 and 7,8-DHF on behavioral sensitization in mice after withdrawal from repeated METH 
exposure. A: Schedule of treatment and behavioral test. Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 days) 
were injected into mice from day 1 to day 5. After 1-week withdrawal, vehicle (10 ml/kg/day), ANA-12 (ANA: 0.5 mg/kg/day), 
or 7,8-DHF (DHF: 10 mg/kg/day) were administered for 14 days (days 12-25). Behavioral tests (METH-induced 
hyperlocomotion) were performed at day 28. B: The established behavioral sensitization after the repeated METH (3 mg/kg/day 
for 5 days) exposure was significantly attenuated by subsequent repeated administration of ANA-12, but not 7,8-DHF. Each 
value is the mean ± S.E.M. (n = 7-9 per group). ***P < 0.001 as compared with METH + vehicle group. C: Schedule of 
treatment and behavioral test. Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 days) were injected into mice from 
day 1 to day 5. After 1-week withdrawal, vehicle (10 ml/kg/day), or ANA-12 (ANA: 0.5 mg/kg/day), were administered for 14 
days (days 12-25). Surgery was performed at day 27, and in vivo microdialysis was performed at day 28. D: A marked increase 
of dopamine in the NAc shell after a METH (1 mg/kg) injection of METH (3 mg/kg/day for 5 days)-treated mice, was 
significantly attenuated by subsequent repeated administration of ANA-12. Each value is the mean ± S.E.M. (n = 5 or 6 per 
group). *P < 0.05, ***P < 0.001 as compared with control (saline + vehicle treated) group. #P < 0.05, ##P < 0.01 as compared 
with METH + vehicle group.  
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No effects of ketamine and paroxetine on depressive-like behavior after METH 
withdrawal 
    The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is the most 
attractive drug for treating treatment-resistant depression (Hashimoto, 2009; 2014; 
Krystal et al, 2013; Yang and Hashimoto, 2014). A single administration of ketamine 
(10 mg/kg, i.p.) confers a rapid and long-lasting antidepressant effect in chronic mild 
stress models of depression (Li et al, 2011; Ma et al, 2013). Three days after the 
repeated administration of METH (3 mg/kg/day for 5 days), saline or ketamine (10 
mg/kg, i.p.) was administered. One-way ANOVA revealed statistical differences among 
the three groups [LMT: F (2, 21) = 3.041, P = 0.069; TST: F (2, 19) = 5.801, P = 0.011; FST: 
F (2, 18) = 5.09, P = 0.018; SPT: F (2, 16) = 6.727, P = 0.008)]. However, post hoc analysis 
showed that a single administration of ketamine (10 mg/kg) had no antidepressant 
effects in depressed mice after METH withdrawal (Figure 5A and 5B).  
Three days after the repeated administration of METH (3 mg/kg/day for 5 days), 
vehicle or the antidepressant paroxetine (10 mg/kg/day for 14 days) was administered. 
Two-way ANOVA revealed statistical differences among the four groups [LMT: METH 
F (1, 28) = 1.003, P = 0.325; paroxetine F (1, 28) = 1.102, P = 0.303; interaction (METH × 
paroxetine) F (1, 28) = 0.295, P = 0.591; TST: METH F (1, 23) = 19.93, P < 0.001; 
paroxetine F (1, 23) = 7.075, P = 0.014; interaction (METH × paroxetine) = F (1, 23) = 
0.074, P = 0.789; FST: METH F (1, 24) = 16.16, P = 0.001; paroxetine F (1, 24) = 0.272, P = 
0.607; interaction (METH × paroxetine) F (1, 24) = 4.188, P = 0.520; SPT: METH F (1, 27) 
= 16.49, P < 0.001; paroxetine F (1, 27) = 0.190, P = 0.666; interaction (METH × 
paroxetine) F (1, 27) = 0.006, P = 0.946). However, the post hoc analysis showed that 
subchronic administration of paroxetine (10 mg/kg/day for 14 days) had no 
antidepressant effects in depressed mice after METH withdrawal (Figure 5C and 5D). 
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Figure 5. Lack of effects of ketamine and paroxetine on depression-like behavior in mice after withdrawal 
from repeated METH exposure.  A: Schedule of treatment and behavioral tests. Saline (10 ml/kg/day for 5 days) or 
METH (3 mg/kg/day for 5 days) were injected into mice from day 1 to day 5. Three days (day 8) after the final injection, 
vehicle (10 ml/kg, i.p.), or ketamine (10 mg/kg, i.p.) was administered. LMT, TST, and FST were performed at 1, 3, 5 hours 
after ketamine injection. SPT was performed at day 9. B: LMT: There were no differences among the three groups. TST and 
FST: Increased immobility time of METH-treated mice was not altered by a single administration of ketamine (10 mg/kg). SPT: 
Decreased sucrose preference of METH-treated mice was not altered by a single administration of ketamine. Each value is the 
mean ± S.E.M. (n = 6-9 per group). *P < 0.05, **P < 0.01, ***P < 0.001 as compared with control (saline-treated) group. N.S.: 
no significance. C: Schedule of treatment and behavioral test. Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 
days) were injected into mice from day 1 to day 5. Saline (Sal: 10 ml/kg/day, i.p.), or paroxetine (Par: 10 mg/kg/day, i.p.) were 
administered for 14 days (days 8-21). Behavioral tests were performed at days 28 (LMT, TST, FST) and 30 (SPT). D: LMT: 
There were no differences among the four groups. TST and FST: Increased immobility time of METH-treated mice was not 
altered by subsequent repeated administration of paroxetine (10 mg/kg/day for 14 days). SPT: Decreased sucrose preference of 
METH-treated mice was not altered by subsequent repeated administration of paroxetine (10 mg/kg/day for 14 days). Each 
value is the mean ± S.E.M. (n = 6-8 per group). **P < 0.01 as compared with control (saline-treated) group. N.S.: no 
significance. SPT: sucrose preference test, LMT: locomotion, TST: tail suspension test, FST: forced swimming test. 
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Effects of repeated administration with ANA-12 and 7,8-DHF on dendritic spine 
alterations and synaptic protein levels in PFC, NAc, hippocampus, and VTA. 
    Repeated treatment with stimulants (e.g., amphetamine, METH) is known to 
increase the number of dendritic branches and the density of dendritic spines in the NAc 
(Robinson and Kolb, 1997; 1999; Zhu et al, 2012). We examined whether the 
subchronic administration of ANA-12 (0.5 mg/kg/day for 14 days) or 7,8-DHF (10 
mg/kg/day for 14 days) had an effect on spine density and synaptic protein GluA1 levels 
in different brain regions (Figure 6A and 6C). One-way ANOVA revealed significant 
differences among the four groups [mPFC: F (3, 16) = 0.956, P =0.438, CA3: F (3, 17) = 
0.968, P = 0.430; DG: F (3, 16) = 3.06, P = 0.580; NAc shell: F (3, 18) = 74.76, P < 0.001; 
NAc core: F (3, 16) = 0.689, P = 0.572; VTA: F (3, 18) = 48.25, P < 0.001)]. The post hoc 
analysis showed that the increase of spine density in the NAc shell and VTA of 
METH-treated mice was significantly attenuated by subsequent repeated administration 
of ANA-12, but not 7,8-DHF (Figure 6B). 
One-way ANOVA revealed statistical differences among the four groups [PFC: F 
(3, 21) = 0.578, P = 0.636; CA3: F (3, 19) = 0.616, P = 0.613; DG: F (3, 21) = 0.774, P = 
0.552; NAc: F (3, 23) = 6.012, P = 0.004]. The post hoc analysis showed that the increase 
of GluA1 protein in the NAc of METH-treated mice was significantly attenuated by 
subsequent repeated administration of ANA-12, but not 7,8-DHF (Figure 6D). 
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Figure 6. Effects of ANA-12 on dendritic changes in the brain regions after withdrawal from repeated 
METH exposure.  A: Schedule of treatment and sample collection. Saline (10 ml/kg/day for 5 days) or METH (3 
mg/kg/day for 5 days) were injected into mice from day 1 to day 5. After 1-week withdrawal, vehicle (Veh: 10 ml/kg/day, i.p.), 
ANA-12 (ANA: 0.5 mg/kg/day, i.p.), or 7,8-DHF (DHF: 10 mg/kg/day, i.p.) were administered for 14 days (days 12-25). 
Sample collection for Golgi staining was performed at days 28. B: PFC, DG, CA3, NAC core: There were no differences 
among the five groups. NAC shell and VTA: Increased spine density in the NAc shell and VTA of METH-treated mice were 
significantly attenuated by subsequently repeated administration of ANA-12, but not 7,8-DHF. Each value is the mean ± S.E.M. 
(n = 5 or 6 per group). ***P < 0.001 as compared with METH + vehicle group. N.S.: no significance. C: Schedule of treatment 
and Western blot analysis. Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 days) were injected into mice from 
day 1 to day 5. After 1-week withdrawal, vehicle (10 ml/kg/day, i.p.), ANA-12 (ANA: 0.5 mg/kg/day, i.p.), or 7,8-DHF (DHF: 
10 mg/kg/day, i.p.) were administered for 14 days (days 12-25). Sample correction for Western blot analysis was performed at 
day 28. D: PFC, DG, CA3: There were no differences among the four groups. NAc: Increased GluA1 protein in the NAc of 
METH-treated mice were significantly attenuated by subsequently repeated administration of ANA-12, but not 7,8-DHF. Each 
value is the mean ± S.E.M. (n = 6-8 per group). **P < 0.01 as compared with METH + vehicle group. N.S.: no significance. 
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A single bilateral injection of ANA-12 into the NAc shell, but not NAc core, 
improves depressive-like behaviors and behavioral sensitization after METH 
withdrawal 
The above data suggest that increased BDNF levels and spine density in the NAc play a 
role in the depression-like behavior in mice treated with METH (3 mg/kg/day for 5 
days). We examined whether ANA-12 could attenuate the depressive-like behavior and 
behavioral sensitization in mice after METH withdrawal. A single bilateral injection of 
ANA-12 (0.1 nmol/L, 0.1 µL/min for 5 min) into the NAc shell significantly (P < 0.01) 
attenuated the increased immobility time of TST and FST, and significantly (P < 0.01) 
increased the reduction in SPT (Figure 7A and 7B). Interestingly, a single bilateral 
injection of ANA-12 into NAc shell showed a long-lasting (>11 days after injection of 
ANA-12 into NAc shell) antidepressant effect (Figure 7B). Next, we examined the 
effect of ANA-12 on the established behavioral sensitization after METH withdrawal. 
Ninety minutes after a single bilateral infusion of ANA-12 (0.1 nmol/L, 0.1 µL/min for 
5 min) into the NAc shell, METH (1 mg/kg, s.c.) was injected to all mice. A single 
bilateral injection of ANA-12 into the NAc shell also significantly (P < 0.001) 
attenuated the behavioral sensitization in mice after METH withdrawal (Figure 7C and 
7D).  
     In contrast, a single bilateral injection of ANA-12 (0.1 nmol/L, 0.1 µL/min for 5 
min) into the NAc core did not attenuate the increased immobility time of TST and FST, 
and the reduction in SPT of METH-treated mice (Figure 7E and 7F). These findings 
suggest that NAc shell, but not NAc core, plays a key role in the METH withdrawal 
symptoms. 
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Figure 7. Effects of bilateral injection of ANA-12 into NAc shell on depression-like behavior and behavioral 
sensitization after withdrawal from repeated METH exposure. A: Schedule of treatment and behavioral tests. 
Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 days) were injected into mice from day 1 to day 5. 
Two days after the final injection, surgery was performed described in the Method section. Vehicle or ANA-12 
was injected bilaterally into the NAc shell. Behavioral tests were performed 1 hr (LMT), 3 hrs (TST), 5 hrs (FST) 
after injection of ANA-12. Then behavioral tests were performed at days 10, 12, and 19 (SPT). B: LMT: There 
were no differences among the three groups. TST, FST: Increased immobility time of METH-treated mice was 
significantly attenuated by a single bilateral injection of ANA-12 into the NAc shell. SPT: Decreased sucrose 
preference of METH-treated mice was significantly improved after a single bilateral injection of ANA-12 into the 
NAc shell. Antidepressant effect of ANA-12 showed a long-lasting (11 days after ANA-12 injection). Each value 
is the mean ± S.E.M. (n = 5-7 per group). **P < 0.01, ***P < 0.001 as compared with METH + vehicle group. 
N.S.: no significance. 
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Figure 7. Effects of bilateral injection of ANA-12 into NAc shell on depression-like behavior and behavioral 
sensitization after withdrawal from repeated METH exposure. C: Schedule of treatment and behavioral test. 
Saline (10 ml/kg/day for 5 days) or METH (3 mg/kg/day for 5 days) were injected into mice from day 1 to day 5. 
Two days after the final injection, surgery was performed described in the Method section. Vehicle or ANA-12 
was injected bilaterally into the NAc shell. METH (1 mg/kg, s.c.) was administered into all mice 60 min after 
injection of ANA-12 into NAc. D: Locomotion was counted for 90 min. Each value is the mean ± S.E.M (n = 5-7 
per group). E: Schedule of treatment and behavioral tests. Saline (10 ml/kg/day for 5 days) or METH (3 
mg/kg/day for 5 days) were injected into mice from day 1 to day 5. Two days after the final injection, surgery was 
performed described in the Method section. Vehicle or ANA-12 was injected bilaterally into the NAc core. 
Behavioral tests were performed 1 hr (LMT), 3 hrs (TST), 5 hrs (FST) after injection of ANA-12. The SPT was 
performed at days 10. F: LMT: There were no differences among the three groups. TST, FST: Increased 
immobility time of METH-treated mice was not altered by a single bilateral injection of ANA-12 into the NAc 
core. SPT: Decreased sucrose preference of METH-treated mice was not altered after a single bilateral injection 
of ANA-12 into the NAc core. Each value is the mean ± S.E.M. (n = 5-7 per group). *P< 0.05, **P < 0.01 as 
compared with Control group. N.S.: no significance. LMT: locomotion, TST: tail suspension test, FST: forced 
swimming test, SPT: sucrose preference test. 
63 
 
 
DISCUSSION 
The major findings of the present study are that increased BDNF-TrkB signaling in 
the NAc shell, but not the NAc core, PFC and hippocampus, plays a role in the 
behavioral abnormalities (depression and sensitization) in mice after repeated METH 
administration and that the TrkB antagonist ANA-12 is a potential therapeutic drug for 
METH withdrawal symptoms. In this study, we found that BDNF levels in the NAc of 
METH-treated mice were significantly higher than those of the control mice, suggesting 
that increased BDNF levels in the NAc are involved in the depression-like behavior 
after METH withdrawal. Furthermore, blocking TrkB with ANA-12 in the NAc shell 
showed therapeutic effects on depression and behavioral sensitization after repeated 
METH exposure, confirming the role of the activated BDNF-TrkB signaling pathway in 
the mechanism of behavioral abnormalities after METH withdrawal. To the best of our 
knowledge, this is the first report which showed that that blocking BDNF-TrkB 
signaling in the NAc shell represents a potential therapeutic approach for behavioral 
abnormalities after repeated METH exposure. Previously, several studies had suggested 
that BDNF-TrkB signaling plays a causal role in the plasticity observed in other abused 
drugs, including cocaine and morphine (Berhow et al, 1995; Graham et al, 2009; Lobo 
et al, 2010). A recent clinical study showed that BDNF serum levels were significantly 
lower in METH abusers (n = 59) during early withdrawal compared with age- and 
sex-matched healthy controls (n = 59) (Chen et al, 2014), suggesting that METH 
abusers suffer from a severe dysfunction of BDNF-TrkB signaling. Taken together, 
these findings identify TrkB antagonists such as ANA-12 as promising therapeutic 
drugs for multiple withdrawal symptoms associated with METH abuse in humans. 
In this study, we found that repeated administration of METH resulted in a 
marked increase of BDNF protein (not proBDNF) and p-TrkB levels in the NAc, 
resulting in the long-lasting depression-like behavior in mice after METH withdrawal. 
Considering the role of BDNF-TrkB signaling in the NAc in depression (Berton et al, 
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2006; Eisch et al, 2003; Nestler and Carlezon, 2006; Krishnan et al, 2007; Yang et al, 
2015; Zhang et al, 2015), our findings suggest that a marked increase of BDNF within 
the NAc by repeated METH exposure contributes to long-lasting behavioral 
abnormalities (depression and sensitization) and that TrkB antagonists confer beneficial 
effects against these behavioral abnormalities by blocking TrkB signaling in the NAc 
shell, but not NAc core. Interestingly, we found that the NMDA receptor antagonist 
ketamine was not an effective antidepressant to treat the depression-like behavior after 
METH withdrawal. In chronic mild stress models of depression (Li et al, 2011; Ma et al, 
2013), a single administration of ketamine confers a rapid and long-lasting 
antidepressant effect by increasing BDNF levels in the PFC and hippocampus. Because 
ketamine’s antidepressant effect was not detected in the METH withdrawal model, it is 
unlikely that BDNF-TrkB signaling in the NAc may be involved in the antidepressant’s 
mechanisms of ketamine.  
      Although some SSRIs, including paroxetine, have been studied as potential 
therapeutic drugs for METH dependence, SSRIs failed to distinguish themselves from 
placebo (Piasecki et al, 2002; Shoptaw et al, 2006). In this study, we observed that 
repeated treatment with paroxetine (10 mg/kg/day for 14 days) had no antidepressant 
effect on the depression-like behavior after METH withdrawal. Because an increase of 
BDNF in the hippocampus by chronic SSRI administration has been implicated in the 
mechanism of antidepressant action of SSRI (Nestler et al, 2002; Hashimoto et al, 2004; 
Duman and Monteggia, 2006), the lack of efficacy of paroxetine for METH-induced 
depression is of great interest. Taken together, it is likely that TrkB antagonists are more 
suitable drugs than the current antidepressants for METH withdrawal symptoms. 
Repeated exposure to METH results in a progressively enhanced and enduring 
behavioral response to the drug, a phenomenon known as behavioral sensitization. A 
number of behavioral, neurochemical, biochemical, and molecular studies have shown 
that the initiation of this complex process involves the interaction of several 
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neurotransmitters, neuropeptides, neurotrophic factors, and their associated receptor 
signaling pathways (Robinson and Becker, 1986; Pierce and Kalivas, 1997; 
Vanderschuren and Kalivas, 2000). Dopamine release and dopamine-induced 
behavioral abnormalities by METH have been reported to be significantly suppressed 
by pretreatment with intra-NAc injections of TrkB antibodies (Narita et al, 2003). In 
this study, we found that behavioral sensitization after repeated METH administration is 
improved after subsequent repeated administration of ANA-12 or a single bilateral 
infusion of ANA-12 into the NAc shell, but not NAc. Furthermore, the in vivo 
microdialysis study showed that an increase of extracellular dopamine release in the 
NAc shell of METH-treated mice was significantly attenuated after subsequent repeated 
administration of ANA-12 or a single bilateral infusion of ANA-12 into the NAc shell. 
These findings add weight to the theory that BDNF-TrkB signaling in the NAc shell 
plays a key role in METH-induced behavioral sensitization in rodents. Therefore, it is 
likely that blocking TrkB signaling in the NAc shell by a TrkB antagonist can attenuate 
the behavioral sensitization after repeated METH administration.  
Deep brain stimulation (DBS) is a neurosurgical intervention in which implanted 
electrodes deliver microelectrical pulses to target areas in the human brain. DBS has 
been used for treatment-refractory patients suffering from substance abuse and 
depression (Luigjes et al, 2012; Pierce and Vassoler, 2013; Millet et al, 2014). The NAc 
is known to mediate the rewarding and reinforcing properties of drugs of abuse and 
constitutes a key target in the treatment of depression, given that anhedonia is one of the 
key defining symptoms of depression (Schlaepfer et al, 2008). Interestingly, DBS of the 
NAc shell, but not the NAc core, significantly attenuates cocaine priming-induced 
reinstatement of drug seeking (Vassoler et al, 2008). In this study, we observed an 
increased spine density in the NAc shell, but not in the NAc core, of the METH-treated 
mice. Furthermore, an increase of the spine density in the NAc shell by repeated METH 
exposure could be attenuated by subsequent repeated administration of ANA-12. 
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Moreover, a single bilateral infusion of ANA-12 into the NAc shell showed a 
long-lasting antidepressant effect for depression-like behaviors after METH 
withdrawal. Taken together, a bilateral infusion of TrkB antagonist into the NAc shell 
is a potential therapeutic approach for patients with severe substance abuse. 
In conclusion, our study demonstrated that an increased BDNF-TrkB signaling in 
the NAc shell may be implicated in the long-lasting behavioral abnormalities 
(depression and sensitization) in mice after the repeated exposure to METH and that 
blockage of TrkB signaling by ANA-12 could attenuate these behavioral abnormalities 
after METH withdrawal. These findings make TrkB antagonists promising therapeutic 
agents for the treatment of multiple withdrawal symptoms associated with METH 
abuse.  
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